Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Taysha Gene Therapies, Inc. | Director | Common Stock | 49.2K | $74.3K | $1.51 | May 29, 2024 | Direct |
Kaleido Biosciences, Inc. | Chief Medical Officer | Restricted Stock Units | 125K | Jan 14, 2022 | Direct | ||
Taysha Gene Therapies, Inc. | Director | Stock Option (right to buy) | 98.4K | May 29, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
TSHA | Taysha Gene Therapies, Inc. | May 29, 2024 | 2 | $0 | 4 | May 31, 2024 | Director |
TSHA | Taysha Gene Therapies, Inc. | Nov 1, 2023 | 1 | $0 | 4 | Nov 3, 2023 | Director |
TSHA | Taysha Gene Therapies, Inc. | Nov 1, 2023 | 0 | $0 | 3 | Nov 3, 2023 | Director |
KLDO | Kaleido Biosciences, Inc. | Jan 14, 2022 | 2 | $0 | 4 | Jan 18, 2022 | Chief Medical Officer |
KLDO | Kaleido Biosciences, Inc. | Dec 15, 2021 | 2 | $0 | 4 | Dec 16, 2021 | Chief Medical Officer |
KLDO | Kaleido Biosciences, Inc. | Dec 15, 2021 | 0 | $0 | 3 | Dec 16, 2021 | Chief Medical Officer |